Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in Refractory Nontuberculous Mycobacterial Lung Disease
NCT04154826Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of efineptakin alfa in nontuberculous mycobacterial lung disease (2 arms), sponsored by RevImmune. Primary endpoint: Proportion of subjects with Acid Fast Bacilli (AFB) sputum culture conversion to negative at 180 days. Started Nov 2020; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on NCT04154826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154826.